{"nctId":"NCT02132169","briefTitle":"A Multi-Center Study Evaluating the Safety of AC-170 0.24%","startDateStruct":{"date":"2014-05"},"conditions":["Atopic Disease (Including Allergic Conjunctivitis)"],"count":512,"armGroups":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL","interventionNames":["Drug: Drug: AC-170 0.24%"]},{"label":"AC-170 0%","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AC-170 0%"]}],"interventions":[{"name":"Drug: AC-170 0.24%","otherNames":["1 drop in each eye 2 times daily for up to 6 weeks"]},{"name":"AC-170 0%","otherNames":["1 drop in each eye 2 times daily for up to 6 weeks"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* at least 2 years of age\n* be able to self-administer eye drops or have a parent/legal guardian available for this purpose\n* if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)\n* have ocular health within normal limits\n\nExclusion Criteria:\n\n* known contraindications or sensitivities to the study medication or its components\n* any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters\n* use of disallowed medication during the period indicated prior to the enrollment or during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 1 (Day 1)","description":"Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.36"},{"groupId":"OG001","value":"0.5","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.25"},{"groupId":"OG001","value":"0.3","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.22"},{"groupId":"OG001","value":"0.3","spread":"0.75"}]}]}]},{"type":"PRIMARY","title":"Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 2 (Day 8)","description":"Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.24"},{"groupId":"OG001","value":"0.3","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.02"},{"groupId":"OG001","value":"0.3","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.90"},{"groupId":"OG001","value":"0.2","spread":"0.63"}]}]}]},{"type":"PRIMARY","title":"Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 3 (Day 22)","description":"Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.13"},{"groupId":"OG001","value":"0.2","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.83"},{"groupId":"OG001","value":"0.2","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.80"},{"groupId":"OG001","value":"0.1","spread":"0.47"}]}]}]},{"type":"SECONDARY","title":"Safety of AC 170 0.024% Compared to Its Vehicle","description":"Safety measures (adverse events) of AC 170 0.024% compared to its vehicle were measured at Visit 1-4 and 5 (for subset of patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":341},"commonTop":["Conjunctival Hyperaemia","Instillation Site Pain","Ocular Hyperaemia","Vision Blurred","Dry eye"]}}}